Rezivertinib T36644
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
5 mg | 1835667-12-3 | ¥2,490.00 | 询底价 |
25 mg | 1835667-12-3 | ¥9,160.00 | 询底价 |
100 mg | 1835667-12-3 | ¥17,500.00 | 询底价 |
50 mg | 1835667-12-3 | ¥11,900.00 | 询底价 |
1 mL | 1835667-12-3 | ¥2,730.00 | 询底价 |
2 mg | 1835667-12-3 | ¥1,470.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Rezivertinib
描述: Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with potent activity against both common activation EGFR and resistance T790M mutations. Additionally, Rezivertinib demonstrates excellent central nervous system (CNS) penetration and exhibits antitumor activity[1][2].
体外活性: Rezivertinib (BPI-7711) selectively inhibits cellular proliferation of EGFR mutations in cell lines: GI50 13.3 nM (PC9, del19), 6.8 nM (HCC827, L858R), 22 nM (NCI-H1975, del19/T790M) and > 1000 nM (A431, EGFR WT)[1].
体内活性: Rezivertinib (BPI-7711; 6.25-25 mg/kg/day; orally; 14 days) shows significant tumor regression[2]. Rezivertinib (12.5 mg/kg/day; orally; 14 days) survives an average of 112% longer in H1975-luc human NSCLC mice model[2]. Rezivertinib (50 mg/kg/day; orally) has anti-tumor efficacy correlated to improved average overall survival of the animals of 115% (28 days vs. 13 days)[2].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 125 mg/mL (256.90 mM)
关键字: Rezivertinib
Rezivertinib T36644信息由TargetMol中国为您提供,如您想了解更多关于Rezivertinib T36644报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途